WallStSmart

HCA Holdings Inc (HCA)vsSyra Health Corp. Class A Common Stock (SYRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Holdings Inc generates 1046122% more annual revenue ($75.60B vs $7.23M). HCA leads profitability with a 9.0% profit margin vs -12.4%. HCA earns a higher WallStSmart Score of 69/100 (B-).

HCA

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.71

SYRA

Avoid

28

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: 0.85
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HCAUndervalued (+59.9%)

Margin of Safety

+59.9%

Fair Value

$1326.31

Current Price

$484.02

$842.29 discount

UndervaluedFair: $1326.31Overvalued

Intrinsic value data unavailable for SYRA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCA5 strengths · Avg: 9.0/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-8.3310/10

Conservative balance sheet, low leverage

Market CapQuality
$108.62B9/10

Large-cap with strong market position

P/E RatioValuation
17.1x8/10

Attractively priced relative to earnings

EPS GrowthGrowth
44.5%8/10

Earnings expanding 44.5% YoY

SYRA2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Areas to Watch

HCA1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

SYRA4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.11M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-36.0%2/10

ROE of -36.0% — below average capital efficiency

Revenue GrowthGrowth
-13.6%2/10

Revenue declined 13.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bull Case : SYRA

The strongest argument for SYRA centers on Price/Book, Debt/Equity.

Bear Case : HCA

The primary concerns for HCA are Altman Z-Score.

Bear Case : SYRA

The primary concerns for SYRA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

HCA profiles as a value stock while SYRA is a turnaround play — different risk/reward profiles.

SYRA carries more volatility with a beta of 3.96 — expect wider price swings.

HCA is growing revenue faster at 6.7% — sustainability is the question.

HCA generates stronger free cash flow (870M), providing more financial flexibility.

Bottom Line

HCA scores higher overall (69/100 vs 28/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HCA Holdings Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

Syra Health Corp. Class A Common Stock

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Syra Health Corp. The company is headquartered in Carmel, Indiana.

Want to dig deeper into these stocks?